Palliative Care in Advanced Heart Failure: A Comprehensive Clinical Review

 Palliative Care in Advanced Heart Failure: A Comprehensive Clinical Review

Authors: Dr. Shekhar Ingle and Team, Doctor’s Forum for All 🏥

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Abstract

Advanced heart failure (AHF) is a progressive, life-limiting condition with a high symptom burden, frequent hospitalizations, and unpredictable illness trajectory. Palliative care should be integrated early alongside optimal medical and device therapy, not reserved for the terminal phase. This article reviews the principles and practical management of symptoms in advanced heart failure, including dyspnoea, pain, fatigue, depression, cachexia, and end-of-life care. Emphasis is placed on evidence-based symptom control, communication, advance care planning, and the role of the interdisciplinary team.

1. Introduction

Heart failure affects over 64 million people worldwide and is a leading cause of hospitalization and death, particularly in older adults [1]. Advanced heart failure (ACC/AHA Stage D or NYHA Class III–IV despite optimal therapy) is characterized by persistent severe symptoms, recurrent decompensations, progressive functional decline, and poor quality of life. Median survival is often less than 12–24 months, yet prognostication is difficult and many patients overestimate their life expectancy [2].

Palliative care aims to improve quality of life for patients and families facing life-threatening illness. In advanced heart failure, palliative care should be delivered concurrently with guideline-directed medical therapy (GDMT), including diuretics, ACE inhibitors/ARBs/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and device therapies where appropriate [3]. Early integration improves symptom control, communication, and may reduce readmissions [4].

2. Disease Trajectory and Triggers for Palliative Care Referral

The heart failure trajectory is often marked by gradual decline punctuated by acute episodes of decompensation, with sudden death possible at any time. This unpredictability makes advance care planning essential.

Palliative care referral should be considered when:

· NYHA Class III–IV symptoms despite optimal medical therapy.

· Recurrent hospitalizations (>2 per year) for heart failure.

· Progressive decline in renal function, weight loss, or frailty.

· Inotrope dependence or consideration of mechanical circulatory support/transplant.

· Implantable cardioverter-defibrillator (ICD) shocks despite optimal therapy.

· Patient or family request for symptom management or goals-of-care discussion.

· Limited life expectancy (e.g., 6–12 months) as estimated by prognostic models (e.g., Seattle Heart Failure Model, MAGGIC score) [5].

3. General Principles of Palliative Care in Advanced Heart Failure

1. Concurrent care: Palliative care is provided alongside cardiology and heart failure management.

2. Interdisciplinary team: Cardiologist, palliative care physician, heart failure nurse, pharmacist, physiotherapist, dietitian, psychologist, social worker, and chaplain.

3. Holistic assessment: Regular evaluation of physical, psychological, social, and spiritual needs.

4. Symptom-driven approach: Focus on patient-reported outcomes and quality of life.

5. Communication and advance care planning: Discuss prognosis, goals, and preferences early, including device deactivation and place of death.

4. Symptom Assessment and Management

4.1 Dyspnoea

Dyspnoea is the most distressing symptom in advanced heart failure, affecting up to 90% of patients at end of life.

Management:

· Optimize heart failure therapy: Diuretics for congestion, ACE inhibitors/ARNIs, beta-blockers, and mineralocorticoid receptor antagonists as tolerated.

· Oxygen: Only if hypoxaemia (SpO₂ ≤ 90%). Routine oxygen for non-hypoxaemic patients is not recommended [6].

· Opioids: Low-dose oral morphine (e.g., 2.5–5 mg every 4 hours as needed) or subcutaneous morphine is effective for refractory dyspnoea without significant respiratory depression [7,8]. Start low and titrate slowly.

· Benzodiazepines: May be used for associated anxiety or panic, but are not first-line for isolated dyspnoea.

· Non-pharmacological: Fan therapy, cool air, positioning (upright or side-lying), energy conservation, and relaxation techniques.

· Acute pulmonary oedema: IV diuretics, nitrates, and non-invasive ventilation in hospital. In the terminal phase, opioids and sedatives may be used for comfort.

4.2 Pain

Pain is under-recognized in heart failure; up to 75% of patients report pain, often from ischaemic heart disease, arthritis, or cardiac cachexia.

Management:

· WHO analgesic ladder: Paracetamol is safe first-line. NSAIDs should be avoided due to nephrotoxicity and fluid retention. Weak opioids (tramadol, codeine) may be used, but caution with renal impairment.

· Strong opioids: Morphine or oxycodone for moderate-to-severe pain. Fentanyl patches may be preferred in stable renal function; transdermal absorption can be unreliable in oedematous or cachectic patients.

· Adjuvants: Gabapentin or pregabalin for neuropathic pain; amitriptyline for neuropathic pain but anticholinergic effects may worsen arrhythmias or urinary retention.

· Non-pharmacological: Physiotherapy, TENS, heat/cold, and cognitive behavioural therapy.

4.3 Fatigue and Weakness

Fatigue is pervasive in advanced heart failure due to low cardiac output, anaemia, deconditioning, depression, and medications.

Management:

· Treat reversible causes: Anaemia (consider iron replacement if ferritin low), thyroid dysfunction, depression, and medication side effects (e.g., beta-blockers).

· Exercise: Supervised cardiac rehabilitation or graded physical activity improves functional capacity and reduces fatigue [9].

· Energy conservation techniques: Prioritize activities, use assistive devices, and plan rest periods.

· Psychological support: Cognitive behavioural therapy and counselling.

· Corticosteroids: Short-term dexamethasone (4–8 mg daily) may improve energy and appetite in the terminal phase, but evidence is limited.

4.4 Depression and Anxiety

Depression occurs in 20–40% of heart failure patients and is associated with worse outcomes.

Management:

· Screening: Use PHQ-9 or HADS regularly.

· Pharmacotherapy: SSRIs (sertraline, citalopram) are first-line and generally safe. Avoid tricyclic antidepressants due to cardiotoxicity.

· Psychotherapy: Cognitive behavioural therapy, supportive counselling, and mindfulness.

· Anxiety: Short-term benzodiazepines for acute anxiety, but risk of respiratory depression and falls. Consider buspirone or SSRIs for chronic anxiety.

4.5 Nausea, Anorexia, and Cachexia

Cardiac cachexia (involuntary weight loss >5% in 12 months) is associated with poor prognosis. Nausea may result from congestion, medications, or renal impairment.

Management:

· Nausea: Treat reversible causes (digoxin toxicity, constipation, uraemia). Use metoclopramide (if no prolonged QT), ondansetron, or haloperidol.

· Anorexia: Small frequent meals, oral nutritional supplements, and appetite stimulants. Megestrol acetate may improve appetite but increases thromboembolic risk; use cautiously.

· Corticosteroids: Dexamethasone 4–8 mg daily can improve appetite and wellbeing in advanced disease.

· Hydration: Encourage oral fluids if not fluid-restricted; in terminal phase, avoid excessive IV fluids which may worsen congestion.

4.6 Constipation

Common due to reduced mobility, low fibre intake, dehydration, and medications (opioids, diuretics).

Management:

· Prophylaxis with opioids: Prescribe laxatives (e.g., macrogol, senna) routinely.

· Titrate laxatives to achieve regular soft stools.

· Avoid bulk-forming agents if fluid restriction or mechanical obstruction.

· Treat faecal impaction with suppositories or enemas if needed.

4.7 Fluid Overload and Peripheral Oedema

Fluid retention causes dyspnoea, oedema, ascites, and discomfort.

Management:

· Diuretics: Optimize oral loop diuretics (furosemide, bumetanide). In advanced disease, subcutaneous furosemide infusion may be used in the community or hospice setting [10].

· Fluid restriction: Usually 1.5–2 L/day, but should be individualised to avoid thirst and dehydration.

· Skin care: Elevate limbs, moisturize, and monitor for cellulitis or skin breakdown.

· In terminal phase: Diuretics may be continued if they improve comfort, but if the patient is bedbound and not drinking, they may be stopped after careful review.

4.8 Sleep Disturbance

Orthopnoea, paroxysmal nocturnal dyspnoea, nocturia, pain, and depression disrupt sleep.

Management:

· Treat underlying causes: Optimize diuretics and timing, pain control, and manage depression.

· Sleep hygiene: Regular schedule, avoid caffeine and alcohol.

· Non-benzodiazepine hypnotics: Short-term zolpidem or melatonin may be used; avoid long-term benzodiazepines due to dependence and falls.

4.9 Cognitive Impairment

Cognitive decline is common in advanced heart failure due to cerebral hypoperfusion, stroke, or comorbidities.

Management:

· Screen for delirium and dementia.

· Treat delirium: Identify and correct causes (infection, hypoxia, medications, urinary retention). Haloperidol or risperidone may be used for agitation.

· Support family with decision-making and provide a calm environment.

5. Device Deactivation and Advanced Therapies

5.1 Implantable Cardioverter-Defibrillators (ICDs)

ICDs prevent sudden death but may cause painful, distressing shocks in the terminal phase. Deactivation is a key part of advance care planning.

· Discuss deactivation early after device implantation, and revisit at each clinical deterioration.

· Deactivation does not hasten death; it prevents painful shocks and allows natural death.

· Procedure: Arrange with cardiology/device clinic. External magnet can temporarily disable ICD in emergency; definitive deactivation should be planned.

· Pacemaker deactivation is more complex and ethically nuanced; usually continued as it does not cause discomfort, but may be turned off after discussion if the patient is dying.

5.2 Mechanical Circulatory Support (LVAD)

Patients with left ventricular assist devices (LVADs) require complex palliative care. End-of-life planning should include LVAD deactivation when appropriate.

5.3 Inotropes

Continuous inotropic support (dobutamine, milrinone) may be used as palliative therapy to improve symptoms and quality of life in selected patients with end-stage heart failure, despite limited survival benefit.

6. Advance Care Planning and Communication

· Early discussion: Initiate advance care planning when the patient is stable, not during a crisis.

· Prognosis: Use validated tools but acknowledge uncertainty. Phrases like "I am worried that your heart is getting weaker" can open conversations.

· Explore goals: "What is most important to you now?" "What are your hopes and worries for the future?"

· Document preferences: Preferred place of care and death, resuscitation status, and views on ventilation, dialysis, and device deactivation.

· Legal aspects: Appoint healthcare proxy or lasting power of attorney.

· Review regularly: Update preferences with clinical changes.

7. End-of-Life Care in Advanced Heart Failure

Recognising the terminal phase can be challenging. Features suggesting imminent death include:

· Progressive decline despite maximal therapy.

· Repeated hospital admissions.

· Worsening renal and hepatic function.

· Cachexia and severe fatigue.

· Refractory dyspnoea at rest.

· Patient expresses desire for comfort-focused care.

Symptom control in the last days of life:

· Dyspnoea: Morphine 2.5–5 mg subcutaneously every 4 hours as needed, or continuous subcutaneous infusion if frequent doses required.

· Pain: Same as dyspnoea; adjust opioids based on prior use.

· Respiratory secretions: Glycopyrronium 0.2–0.4 mg subcutaneously every 6 hours as needed.

· Agitation/terminal restlessness: Midazolam 2.5–5 mg subcutaneously every 2–4 hours as needed, or continuous infusion.

· Nausea/vomiting: Haloperidol 0.5–1.5 mg subcutaneously every 8 hours as needed.

· Stop non-essential medications: Discontinue routine cardiovascular medications that do not provide immediate symptom benefit (e.g., statins, aspirin, ACE inhibitors) to reduce treatment burden [11].

· Fluid management: Avoid intravenous fluids unless for comfort. Diuretics may be continued if they relieve dyspnoea or oedema.

Care of the family: Provide emotional support, information, and bereavement follow-up.

8. Integration of Palliative Care in Heart Failure Services

· Primary palliative care: Heart failure teams trained in basic symptom management, communication, and advance care planning.

· Specialist palliative care: Referral for complex symptoms, existential distress, or end-of-life care.

· Shared care models: Combined heart failure–palliative care clinics improve quality of life and reduce readmissions [4].

· Community support: Heart failure nurses, hospice at home, and telehealth monitoring.

9. Conclusion

Advanced heart failure is a life-limiting condition with a high symptom burden and unpredictable course. Palliative care should be integrated early, alongside optimal medical and device therapy, to improve quality of life, support families, and ensure goal-concordant care. Clinicians must be skilled in managing dyspnoea, pain, fatigue, depression, and other symptoms, while proactively addressing advance care planning and device deactivation. A multidisciplinary, patient-centred approach is essential.

References

1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7

2. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA. 2008;299(21):2533-2542. doi:10.1001/jama.299.21.2533

3. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012

4. Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70(3):331-341. doi:10.1016/j.jacc.2017.05.030

5. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34(19):1404-1413. doi:10.1093/eurheartj/ehs337

6. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784-793. doi:10.1016/S0140-6736(10)61115-4

7. Johnson MJ, McDonagh TA, Harkness A, et al. Morphine for the relief of breathlessness in patients with chronic heart failure—a pilot study. Eur J Heart Fail. 2002;4(6):753-756. doi:10.1016/s1388-9842(02)00158-0

8. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-944. doi:10.1136/thorax.57.11.939

9. O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301(14):1439-1450. doi:10.1001/jama.2009.454

10. Beattie JM, Johnson MJ. Subcutaneous furosemide in advanced heart failure: has clinical practice run ahead of evidence base? BMJ Support Palliat Care. 2012;2(1):5-6. doi:10.1136/bmjspcare-2011-000145

11. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691-700. doi:10.1001/jamainternmed.2015.0289